Apolipoprotein L1: From obscurity to consistency to controversy

Kidney International

Volumn 87, Issue 1, 2015, Pages 14-17

  Lipkowitz, Michael S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOL1 GENE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 22; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GLOMERULUS FILTRATION RATE; HUMAN; MORTALITY; REVIEW; RISK REDUCTION; ATHEROSCLEROSIS; CHRONIC KIDNEY FAILURE; FEMALE; GENETICS; KIDNEY DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; AFRICAN AMERICAN; ALLELE; GENOTYPE; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; APOLIPOPROTEIN L1;

APOLIPOPROTEINS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY DISEASES; LIPOPROTEINS, HDL; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84920134372     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.319     Document Type: Note

References (21)

1. Klag MJ, Whelton PK, Randall BL et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293-1298.
2. Freedman BI, Spray BJ, Tuttle AB et al. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis 1993; 21: 387-393.
3. Kopp JB, Smith MW, Nelson GW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184.
4. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
5. Tzur S, Rosset S, Shemer R et al. Missense mutations in The APOL1 gene are highly associated with end stage kidney disease risk previously attributed to The MYH9 gene. Hum Genet 2010; 128: 345-350.
6. Kopp JB, Nelson GW, Sampath K et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22: 2129-2137.
7. Lipkowitz MS, Freedman BI, Langefeld CD et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and The rate of kidney function decline in African Americans. Kidney Int 2013; 83: 114-120.
8. Lin CP, Adrianto I, Lessard CJ et al. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 2012; 13: 232-238.
9. Estrella MM, Wyatt CM, Pearce CL et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int 2013; 84: 834-840.
10. Foster MC, Coresh J, Fornage M et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 2013; 24: 1484-1491.
11. Parsa A, Kao WH, Xie D et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196.
12. Friedman DJ, Kozlitina J, Genovese G et al. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011; 22: 2098-2105.
13. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
14. Mehrotra R, Kermah D, Fried L et al. Racial differences in mortality among those with CKD. J Am Soc Nephrol 2008; 19: 1403-1410.
15. Hui X, Matsushita K, Sang Y et al. CKD and cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study: interactions with age, sex, and race. Am J Kidney Dis 2013; 62: 691-702.
16. US Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in The United States. National Institute of Diabetes and Digestive and Kidney Diseases. National Institutes of Health: Bethesda, MD, USA, 2011.
17. Madhavan SM, O'Toole JF, Konieczkowski M et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011; 22: 2119-2128.
18. Monajemi H, Fontijn RD, Pannekoek H et al. The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics 2002; 79: 539-546.
19. Ito K, Bick AG, Flannick J et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 2014; 114: 845-850.
20. Freedman BI, Langefeld CD, Lu L et al. APOL1 associations with nephro-pathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int 2015; 87: 176-181.
21. Langefeld CD, Divers J, Pajewski NM et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in The Systolic Blood Pressure Intervention Trial. Kidney Int 2015; 87: 169-175.